Valeant Pharmaceuticals Intl (VRX) Analysts See Upside; Versar (VSR) Inks Multi-Year Deal

Analysts at RBC Capital Markets reiterated a Sector Perform rating while reducing their price target on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares from $21.00 to $18.00. However, the brokerage firm’s new price objective suggests a potential upside of more than 60% from the stock’s current price levels.

The Canadian pharmaceutical and medical device company said a couple days ago that it has completed its previously announced package of refinancing transactions.

VRX stock is changing hands in positive territory by 2.61% (or +$0.28) at $10.99 with 6.34M shares traded so far on Thursday.

Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, OTC products, and medical devices worldwide, has 341.19M shares outstanding and VRX stock 52-week range is from $10.35 to $38.50 per share.



Shares of Versar, Inc. (NYSEMKT:VSR) climbed over 36% to touch the $2.14 mark in early trade Thursday after the company said that it has reached a multiyear deal – valued at more than $2.3 million – with the U.S. Army Corps of Engineers to provide engineering and project management services in Afghanistan.

VSR stock is currently trading at $2.01, up $0.44 (or +28.03%) and 4.49M of its shares changed hands so far, representing a large increase in activity versus its average volume (3m) of 259,082 shares.

Versar, a global project management company providing solutions to government and commercial clients, has 9.89M shares outstanding and VSR stock one-year range is between $0.90 and $3.25 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at